Innospecs Bioresearch Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.90 M
- Revenue Growth -19.14%
- Profit Growth 38.64%
- Ebitda 322.68%
- Net Worth -42.12%
- Total Assets 2.39%
About Innospecs Bioresearch
Innospecs Bioresearch Private Limited (IBPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 10 May 2019 (Five years and nine months 14 days old ). Its registered office is in Tiruvallur, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹6.90 M.
Viswanathan Sekarbabu and Vijayalakshmi serve as directors at the Company.
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U73100TN2019PTC129205
- Company No.
129205
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 May 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Innospecs Bioresearch?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Viswanathan Sekarbabu  | Director | 10-May-2019 | Current |
| Vijayalakshmi | Director | 10-May-2019 | Current |
Financial Performance of Innospecs Bioresearch.
Innospecs Bioresearch Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 19.14% decrease. The company also saw a substantial improvement in profitability, with a 38.64% increase in profit. The company's net worth observed a substantial decline by a decrease of 42.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Innospecs Bioresearch?
In 2020, Innospecs Bioresearch had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Novares Lab Private LimitedViswanathan Sekarbabu is a mutual person
Charges (Loans)
₹6.90 M
₹0
Charges Breakdown by Lending Institutions
- City Union Bank Limited : 0.69 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Aug 2024 | City Union Bank Limited | ₹1.50 M | Open |
| 07 May 2020 | City Union Bank Limited | ₹5.40 M | Open |
How Many Employees Work at Innospecs Bioresearch?
Unlock and access historical data on people associated with Innospecs Bioresearch, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Innospecs Bioresearch, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Innospecs Bioresearch's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.